Please login to the form below

Not currently logged in
Email:
Password:

Shire makes board changes

UK-based pharmaceutical company Shire has revealed its board succession plans

UK-based pharmaceutical company Shire has revealed its board succession plans.

Dr James H Cavanaugh will retire as non-executive chairman and Matthew Emmens will succeed him, while Angus Russell will take over from Emmens as CEO.

David Kappler will be appointed as deputy chairman in addition to his existing role as senior independent director. These appointments have the unanimous support of the directors.

The changes will become effective at Shire's AGM to be held in June 2008.

Cavanaugh has been chairman of Shire since 1999 and will have been a member of the board for 11 years when he retires.

Emmens, who is currently Shire's CEO, has 34 years of industry experience and since joining the company in 2003 has successfully led the company through a period of significant strategic development, including a number of important M&A transactions. He also has valuable non-executive board experience in his continuing roles on the boards of Incyte and Vertex Pharmaceuticals.

Shire's new CEO Angus Russell, who has been CFO since 1999, has eight years experience as the company's CFO and executive board director and has 27 years experience in the pharmaceutical industry including working for ICI, Zeneca and AstraZeneca in finance, strategy and marketing.

Russell has been a lead member of the Shire Management Committee, which devised and implemented Shire's long term focused business strategy. The company is now working to identify a replacement CFO in order to ensure an orderly succession.

Shire is trading in line with the guidance given on 1 November 2007 when it stated that revenue growth for the year was expected to be at least 30 per cent.

13th December 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...